Anidulafungin liposome nanoparticles exhibit antifungal activity against planktonic and biofilm Candida albicans

dc.contributor.authorVera-González, Noel
dc.contributor.authorBailey-Hytholt, Christina M.
dc.contributor.authorLanglois, Luc
dc.contributor.authorde Camargo Ribeiro, Felipe [UNESP]
dc.contributor.authorde Souza Santos, Evelyn Luzia [UNESP]
dc.contributor.authorJunqueira, Juliana Campos [UNESP]
dc.contributor.authorShukla, Anita
dc.contributor.institutionBrown University
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2020-12-12T02:43:52Z
dc.date.available2020-12-12T02:43:52Z
dc.date.issued2020-11-01
dc.description.abstractFungal infections can cause significant patient morbidity and mortality. Nanoparticle therapeutics have the potential to improve treatment of these infections. Here we report the development of liposomal nanoparticles incorporating anidulafungin, a potent antifungal, with the goal of increasing its solubility and aiding in localization to fungi. Liposomes were fabricated with three concentrations of anidulafungin yielding monodisperse ~100 nm unilamellar vesicles. All three formulations inhibited planktonic Candida albicans growth at a minimum inhibitory concentration equivalent to free drug. All three formulations also disrupted preformed C. albicans biofilms, reducing fungal burden by as much as 99%, exhibiting superior biofilm disruption compared with free drug. Liposome formulations tested in vivo in C. albicans infected Galleria mellonella wax moth larvae demonstrated increased survival compared to free drug equivalents, leading to a survival of 33 to 67% of larvae over 7 days depending on the liposome utilized compared with only 25% survival of larvae administered free drug. Liposomal formulations along with free anidulafungin did not cause red blood cell lysis. Ultimately, the liposome formulations reported here increased anidulafungin solubility, displayed promising efficacy against planktonic and biofilm C. albicans, and improved the survival of C. albicans–infected G. mellonella compared to free anidulafungin.en
dc.description.affiliationSchool of Engineering Center for Biomedical Engineering Institute for Molecular and Nanoscale Innovation Brown University
dc.description.affiliationDepartment of Chemistry Brown University
dc.description.affiliationInstitute of Science and Technology São Paulo State University (UNESP)
dc.description.affiliationUnespInstitute of Science and Technology São Paulo State University (UNESP)
dc.description.sponsorshipNational Science Foundation
dc.description.sponsorshipOffice of Naval Research
dc.description.sponsorshipIdNational Science Foundation: 1644760
dc.description.sponsorshipIdOffice of Naval Research: N000141712651
dc.format.extent2263-2276
dc.identifierhttp://dx.doi.org/10.1002/jbm.a.36984
dc.identifier.citationJournal of Biomedical Materials Research - Part A, v. 108, n. 11, p. 2263-2276, 2020.
dc.identifier.doi10.1002/jbm.a.36984
dc.identifier.issn1552-4965
dc.identifier.issn1549-3296
dc.identifier.scopus2-s2.0-85086326351
dc.identifier.urihttp://hdl.handle.net/11449/201864
dc.language.isoeng
dc.relation.ispartofJournal of Biomedical Materials Research - Part A
dc.sourceScopus
dc.subjectanidulafungin
dc.subjectCandida albicans
dc.subjectfungal infection
dc.subjectGalleria mellonella
dc.subjectliposomal nanoparticles
dc.titleAnidulafungin liposome nanoparticles exhibit antifungal activity against planktonic and biofilm Candida albicansen
dc.typeArtigo
unesp.author.orcid0000-0002-5544-7729[7]

Arquivos